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Many neurosurgery patients may have unrecognized diabetes or may develop stress-related hyperglycemia in the perioperative
period. Diabetes patients have a higher perioperative risk of complications and have longer hospital stays than individuals without
diabetes. Maintenance of euglycemia using intensive insulin therapy (IIT) continues to be investigated as a therapeutic tool to
decrease morbidity and mortality associated with derangements in glucose metabolism due to surgery. Suboptimal perioperative
glucose control may contribute to increased morbidity, mortality, and aggravate concomitant illnesses. The challenge is to
minimizetheeﬀectsofmetabolicderangementsonsurgicaloutcomes,reducebloodglucoseexcursions,andpreventhypoglycemia.
Diﬀerences in cerebral versus systemic glucose metabolism, time course of cerebral response to injury, and heterogeneity of
pathophysiology in the neurosurgical patient populations are important to consider in evaluating the risks and beneﬁts of IIT.
While extremes of glucose levels are to be avoided, there are little data to support an optimal blood glucose level or recommend
a speciﬁc use of IIT for euglycemia maintenance in the perioperative management of neurosurgical patients. Individualized
treatment should be based on the local level of blood glucose control, outpatient treatment regimen, presence of complications,
nature of the surgical procedure, and type of anesthesia administered.
1.Introduction
Several observational and interventional studies have indi-
cated that hyperglycemia (hyperG) in diabetic and non-
diabetic neurosurgical patients is associated with adverse
outcomes, such as an increased prevalence of complications,
prolonged hospital stay, and higher mortality rates [1–5].
In addition there are deleterious eﬀects of glucose deﬁcit
on brain metabolism [6, 7]. Individuals with previously
unknown hyperG are at greater risk than those with pre-
existing diabetes mellitus (DM) [8]. Available evidence
shows that hyperG has negative consequences on the whole
organism, including the brain [9–12]. Undiagnosed DM and
hospital-induced hyperG increase postoperative complica-
tions, hospital costs, and length of stay [13–15]. hyperG is
closely linked to prognosis in diﬀerent brain injury scenarios
[16]. Nevertheless, no consensus exists as to whether hyperG
is directly responsible for poor outcomes or if it is just an
epiphenomenon of brain damage [10–12, 16]. It has been
hypothesized, therefore, that strict blood glucose control
could have a favorable impact on patient outcome [11].
Consequently, increasing interest has evolved for tight blood
glucose control using intensive insulin therapy (IIT) in
neurocritically ill patients. Tight blood glucose control has
been deﬁned as glucose controlled within a range of 80
to 110mg/dL (4.40 to 6.10mmol/L). However, more recent
datasuggestpossibledeleteriouseﬀectsofIITonbraintissue.
Todate,solidclinicalevidencetojustifyIITinneurocritically
ill patients does not exist [4, 16].
Caution is necessary when generalizing IIT clinical stud-
ies from critical ill patients to neurosurgical patients since
brain glucose metabolism is often altered by neurological
injury. A persistent hyperG creates numerous untoward
consequences, while iatrogenic hypoglycemia (hypoG) may
initiate a metabolic crisis in the brain that is even worse [16].
Moreover, the upper and lower thresholds of plasma glucose2 Anesthesiology Research and Practice
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Figure 1: Causes and consequences of hyperglycemia. Where SIRS: Systemic inﬂammatory response syndrome.
fortheseadverseeﬀectsarenotclearlydeﬁnedandperipheral
glucose measurements do not consistently correlate with
brain glucose levels [12, 13, 16, 17].
Improving blood glucose control in the perioperative
period could mitigate many of the detrimental consequences
of hyperG [12, 13, 16, 17]. In diabetic patients, concomitant
conditions, such as obesity, hypertension, renal insuﬃciency,
and coronary artery disease, increase perioperative risk [13–
15]. Surgery is a stressful event that leads to temporary
disruption of oral intake and frequently requires adjust-
ment of antidiabetic therapy [14, 15]. To minimize the
surgical complications due to metabolic derangements and
the eﬀects of surgery on glycemic control, level of blood
glucose control, outpatient treatment regimen, presence of
complications, nature of the surgical procedure, inpatient
glucose response, and type of anesthesia should be taken into
account.
This paper focuses on perioperative glucose control in
neurosurgical patients and glucose management during the
perioperative period. In addition, it features a summary of
guidelines for speciﬁc neurosurgical pathologies in the acute
(perioperative) period.
2. Causesof Glucose Variationsduring
the PerioperativePeriodin Neurosurgery
2.1. Surgical Stress and Glucose Levels
2.1.1. Hyperglycemia. There is no unanimous and clear def-
inition about hyperG or hypoG in the non-DM population,
nor is it well established when to start treatment. The Ameri-
can Diabetes Association consensus recently established the
presence of hyperG and patient treatment threshold when
blood glucose values exceed 140mg/dL (7.8mmol/L) in two
or more plasma samples [8].
Thestressofsurgeryactivatesaneuroendocrineresponse
that antagonizes the action of insulin and predisposes the
patienttohyperGandketoacidosis (Figure 1).Consequently,
an increase of the secretion of counterregulatory hormones
(e.g., epinephrine, cortisol) can be observed [16, 18, 19].
Stress also induces the development of insulin resistance,
generated by proinﬂammatory cytokines [20, 21] or caused
iatrogenically by commonly used drugs (e.g., dopamine,
noradrenaline, corticosteroids, thiazides, and dextrose-
containing solutions) [9, 18, 22]. Stress-induced hyperG
may cause endothelial cell dysfunction, defects in immune
function, increased oxidative stress, prothrombotic changes,
cardiovasculareﬀects,andspeciﬁcbrainarea(insularcortex)
injury or a direct hypothalamic damage/irritation of glucose
regulatory centers [23–25]. hyperG has been shown to
aggravate these deleterious eﬀects, whereas optimization of
glucose control has been shown to reverse them.
2.1.2. Hypoglycemia. hypoG is deﬁned as a blood glucose
value of <70mg/dL (<3.9mmol/L) [8]. hypoG is a common,
multifactorial, and avoidable event. It can occur under any
circumstances, although the DM population is the most
susceptible. There are no speciﬁc data about its incidence
in neurosurgical patients, but it is well known that hypoG
events worsen prognosis [13, 26, 27]. The hypoG-associatedAnesthesiology Research and Practice 3
risk is greater during the perioperative period, when general
anesthesiamaymaskthesymptomsanddelayitsrecognition.
Table 1 shows the most common causes of hypoG in these
patients.
2.2. Surgical Risks and Beneﬁts of Improved Glucose Control.
Patients with diabetes have more comorbidities compared
with the general population, such as obesity, hyperten-
sion, sleep apnea, cardiovascular disease, congestive heart
failure, undetected atherosclerosis (coronary, cerebral, and
peripheral), and renal insuﬃciency. Diabetic autonomic
neuropathy (advanced cardiac, respiratory, and gastroin-
testinal autonomic neuropathy) can lead to hemodynamic
instability, abnormal gut motility, and erroneous glucose
levels. In addition, inadequate glucose control leads to
increased risk of infectious complications [14, 15].
T h eb e n e ﬁ t so fi m p r o v e db l o o dg l u c o s ec o n t r o la f t e r
neurosurgery include a lower rate of craniotomy wound
infections, reduced length of stay, and reduced hospital cost
[14, 15]. Decreased bloodstream and nosocomial infections,
acute renal failure, ventilatory support, blood transfusions,
critical illness polyneuropathy, and duration of stay in the
neurocriticalintensivecareunithavealsobeendemonstrated
[5, 28, 29].
2.3. Diabetes and Increased Risk of Adverse Outcomes in Neu-
rosurgery. DM is a risk factor for suboptimal perioperative
outcomes in patients undergoing neurosurgery [15, 30].
Several studies have identiﬁed an association between dia-
betes and infectious complications after major spine surgery
[31]. Patients with DM also have an increased frequency of
complications, both major (e.g., wound infection, peripheral
nerve root lesion, cardiac arrhythmia, acute renal failure,
cerebrovascular accident) and minor (e.g., urinary tract
infection,paralyticileus,electrolytedeﬁciencies)[13,17,32].
2.4. Glucose Control during Perioperative Period in Neuro-
surgery. Clinical consensus regarding perioperative glucose
control in critically ill patients is lacking, especially in
the neurosurgical population [12–14, 16, 30, 33]. There
are no clinical studies in neurosurgical patients that have
demonstrated signiﬁcantly improved outcome with IIT, and
those data available were collected from retrospective or
small studies [32, 34, 35]. Furthermore, the heterogeneity
of pathologies in neurologic surgery suggests caution in
the generalization of other study results to this patient
population: peripheral and cerebral glucose values do not
correlate or correlate inversely; a normal cerebral glucose
level is poorly deﬁned, and the optimal level in the presence
of anesthesia or brain pathology is unknown [12–14, 16, 30,
33].Inaddition,nodataexisttoguideanytypeofdiﬀerential
management with IIT or ﬂuid therapy in neurosurgical
patients with or without preexisting DM.
2.5. Preoperative Management: Patient Evaluation
2.5.1. Patient Evaluation. Careful preoperative evaluation is
essentialinpatientswithDMtoidentifypreviouslyunknown
Table 1: Hypoglycemia causes in neurocritical care patients.
(i) Starvation
Prolonged hospitalization
Pregnancy
(ii) Drug Induced
Insulin (intensive insulin therapy)
Hypoglycemic agents
Alcohol
Etomidate
Beta blockers
Cyproﬂoxacin
Salicylates
Enalapril
Warfarin
Acetaminophen
(iii) Sepsis
(iv) Renal dysfunction
(v) Hepatic dysfunction
(vi) Endocrine
Hypopituitarism
Adrenal insuﬃciency
Hypothyroidism
Hyperinsulinemia: parenteral nutrition
(vii) Idiopathic
(viii) Iatrogenic
complications and to manage comorbidities [14, 15, 30]. For
elective surgery, it is prudent to organize a multidisciplinary
team. There are neither guidelines nor large-scale trials that
support one treatment plan. Blood glucose control in the
perioperative period must be approached individually [14,
15, 30].
Before a planned surgical procedure, the patient’s blood
glucoseshouldbeascloseaspossibletothatadvocatedbythe
American Diabetes Association [8, 14, 15, 30]. These targets
include glycosylated hemoglobin (Hgb A1C) <7.0%, average
preprandial plasma glucose between 90 and 130mg/dL (5.0
and 7.2mmol/L), and average postprandial plasma glucose
<180mg/dL (10.0mmol/L) [8, 14]. Elective surgical proce-
dures should be scheduled early in the day for patients with
DM [15]. It may be advisable to delay elective surgery until
satisfactory glucose control has been obtained. Glycemic
control can typically be achieved with an insulin drip within
a few hours. Cardiovascular disease can manifest atypically,
occur at a relatively young age, and remain asymptomatic in
patients with DM. The neurosurgeon and neurointensivist
should seriously evaluate symptoms such as chest pain,
exertional dyspnea, and orthopnea. Electrocardiography and
stress testing with or without cardiac imaging may be
warranted in high-risk patients with multiple risk factors.
Patients with peripheral or cardiac autonomic neuropathy
are prone to intraoperative hypotension, perioperative car-
diac arrhythmia, gastroparesis, hypoG unawareness, and loss
of glucose counterregulation [15]. The presence of resting
tachycardia, orthostatic hypotension and loss of heart rate4 Anesthesiology Research and Practice
Table 2: Preoperative evaluation of the neurosurgical patient.
(i) Type II diabetics, noninsulin dependents: stop all oral
antidiabetic agents. In elective surgeries, hold oral antidiabetic
agents 24 hours before intervention especially those such as
chlorpropamide with a long half-life.
(ii) Type II diabetics, insulin dependents: for elective short
procedures (<2 hours), suspend regular insulin. Administer
only 2/3 of the long-acting insulin (NPH) or give the full dose of
basal insulin (glargine, levemir), and start nutrition 12 hours after
surgery.
(iii) Type I or II diabetics: for long surgeries or emergencies:
only use regular insulin according to unit’s protocol.
variability signal the potential for intraoperative problems.
Serum creatinine level may not be a sensitive indicator of
true kidney function in elderly patients with DM. A 24-hour
urine collection may be indicated when there is an elevated
serum creatinine level, proteinuria, or concomitant long-
standing or poorly controlled hypertension. Insulin action is
prolonged in renal impairment, promoting unpredictability
of blood glucose and hypoglycemia. A practical way of action
is reported in Table 2. It should be remembered that type II
diabeticsarevulnerabletoanexaggeratedvariabilityinblood
glucose levels possibly because surgical stress augments
insulin resistance [14, 18, 19].
2.5.2. Hyperglycemia Management: Pharmacologic Agents
Antidiabetic Agents (ADA). The characteristics of currently
available ADA, including the mechanism of action, duration
of eﬀects, dosing, and adverse eﬀects, have been described in
detail elsewhere [36]. Metformin and sulfonylureas should
be withheld 24 hours before surgery [14, 36]. The long-
acting sulfonylureas (e.g., chlorpropamide and glyburide)
can cause prolonged hypoG and should be withheld for
48 to 72 hours [14, 36, 37]. Lactic acidosis is a rare but
s e r i o u ss i d ee ﬀect of metformin, especially in elderly persons
with compromised kidney function [36, 37]. Metformin
may be restarted 48 hours after surgery, with the ﬁrst
meal, provided that hemodynamic stability is maintained
and kidney function remains normal [14, 15, 30]. The
thiazolidinediones (TZDs (e.g., rosiglitazone, pioglitazone))
are insulin-sensitizing agents that can cause ﬂuid retention,
intravascular volume expansion, and dilutional anemia [36,
37]. They can trigger pulmonary edema and congestive
heart failure in susceptible patients, especially when used
in conjunction with insulin. For this reason, they are
contraindicated in patients classiﬁed as New York Heart
Association class 3 and 4 congestive heart failure [36, 38].
TZDs should be restarted only after postoperative recovery
is complete and there is no evidence of cardiopulmonary
compromise or ﬂuid overload [14, 15, 30, 36, 37]. The
recently introduced incretin-based treatments are becoming
popular as add-on medications in patients who do not
achieve glucose goals with traditional oral therapy [36, 37].
Theseinclude exenatide,administered bydailysubcutaneous
(SC)injection,andtheoralagentsitagliptin[36,37].Patients
should discontinue these drugs 24 to 36 hours prior to
surgeryandrestarttheoralantidiabeticsafterdischargefrom
the hospital [14, 36, 37].
In conclusion, ADAs do not have any use in critical
pathologies, particularly during the perioperative period
because of their unpredictable pharmacokinetics and phar-
macodynamics [36, 37]. They interact with many drugs and
their metabolism is inﬂuenced by increased capillary perme-
ability or by hepatic and/or renal dysfunction [14, 36, 37].
Furthermore, these drugs act by promoting the secretion of
insulinand/orbyincreasingthefunctionalityofitsreceptors.
During surgery both mechanisms are antagonized secondary
to the stress response that decreases insulin secretion and
increases resistance to insulin receptors [17, 39–41]. Finally,
ADA can induce a more severe, prolonged, and often lethal
hypoG in neurocritical patients [6, 7, 36, 37, 42].
Insulin. Insulin remains the mainstay of treatment for inpa-
tients with perioperative hyperG. It is powerful, immediately
eﬀective, and has few contraindications or drug interactions.
Insulin is the preferred medication in critically ill patients
and in those with hepatorenal disease, cardiovascular limi-
tations, or hemodynamic compromise [8, 14, 15].
2.6. Intraoperative Glucose Management and Postoperative
Care. hyperG during neurosurgical procedures is best man-
aged with a continuous IV insulin infusion. For an insulin
drip, 100U regular insulin can be added to 100mL of IV
ﬂuid, thus achieving a concentration of 1U/mL. Insulin is
then given via infusion at a calculated rate. Alternatively, an
empirical starting rate is 0.02U/kg/h, titrated subsequently
to achieve the goal glucose range. The infusion should be
started well in advance of the procedure (preferably 2 to 3
hours) to allow titration to the desired glucose range. Hourly
glucose readings are done intraoperatively; the insulin rate
is adjusted to maintain the blood glucose within the target
range. Insulin drip corrections are based on diverse moni-
toring schemes [8, 14, 15, 17]. The reactive approach delays
insulin therapy until hyperG appears, while the proactive
approach maneuvers blood glucose into a predeﬁned target
range [43]. Tables 3 and 4 report the reactive and proactive
algorithms, respectively [44]. Another approach is to take
initial measured blood glucose values and multiply them
with a predeﬁned multiplier. This approach has been shown
to shift plasma glucose into a predeﬁned target range within
a few hours. Such a protocol can be applied manually as a
standard column-based protocol (paper protocol) or can be
driven by computer-guided support [45]. A recent study has
shown that the computer-based algorithm resulted in tighter
glycemic control without an increased risk of hypoglycemic
events compared to the standard paper protocol [46].
Patients who are undergoing elective surgery and whose
blood glucose is well controlled (as reﬂected by ﬁngerstick
readings and A1C values) without the use of insulin in the
outpatient setting may not require an insulin drip and can be
managed with SC supplemental insulin therapy [14, 15].
Postoperatively, the insulin infusion is continued at the
physician’sdiscretion.Inthepresenceofstablebloodglucose,
insulin drip is converted to a subcutaneous insulin regimenAnesthesiology Research and Practice 5
Table 3: Reactive regimen (according to monitorized values). The
measurement unit used for indicating the concentration of blood
or plasma glucose can either have a weight dimension (mg/dL) or a
molarity (mmol/L).
Glucose value Insulin dose
mmol/L∗ mg/dL† IU
≤8.3 ≤150 —
8.4–11.1 151–200 5
11.2–13.9 201–250 10
13.93–16.7 251–300 15
16.71–19.4 301–350 20
Exactconversionofglucosevaluesfrommg/dLtommol/Landviceversaare
as follows:
∗mmol/l = mg/dL × 0.0555,
†mg/dL = mmol/L × 18.0182
Table 4: Proactive regimen: dilute 100U of insulin in 100mL of
isotonic saline solution 0.9% (1U = 1mL). Administer via infusion
pump according to the following scheme. The measurement
unit used for indicating the concentration of blood or plasma
glucose can either have a weight dimension (mg/dL) or a molarity
(mmol/L).
Glucose value Insulin infusion rate
mmol/L mg/dL IU/h
8.3–9.4 150–169 2
9.43–11.0 170–199 3
11.1–13.8 200–249 4
13.9–16.6 250–299 6
16.7–22.1 300–399 8
22.2+ 400+ 10
Exactconversionofglucosevaluesfrommg/dLtommol/Landviceversaare
as follows:
∗mmol/L = mg/dL × 0.0555,
†mg/dL = mmol/L × 18.0182.
with a basal insulin dose and bolus/nutritional insulin dose.
Basal insulin can be given as glargine, levemir, or neutral
protamine Hagedorn (NPH). Bolus/nutritional insulin can
be either given as regular insulin or as one of the insulin
analogs such as glulisine, aspart, or lispro. Regular insulin is
the preferred drug if the patient continues to be on enteral
tube feeding. However, if the patient resumes his regular
diet,insulinanalogsareadvantageousduetotheirimmediate
eﬀect [14, 15].
When transitioning from IV to SC insulin, the drip
should continue and overlap with the ﬁrst SC dose of long-
acting(basal)insulinfortwotofourhours.Failuretooverlap
IV and SC insulin can result in extreme hyperglycemia or
diabetic ketoacidosis (DKA). Usually, ADA are restarted after
the ﬁrst proper food intake if there are no contraindications
[14, 15, 36, 37].
In the presence of reactive hypoG, we recommend the
scheme depicted in Table 5.
2.6.1. Impact of Anesthetics Agents on Systemic and Cerebral
Metabolism of Glucose. Anesthetics inﬂuence systemic and
Table 5: Hypoglycemia management.
Administer hypertonic dextrose (50%) according to the following
formula:
(100 − glycemia) × 0.3 = mL in IV bolus
Check plasma glucose every 30 minutes
If glucose < 60mg/dL (3.3mmol/L), repeat the IV bolus step
Overcorrection will be avoided in all cases.
brain metabolism. Although most of these agents have
depressor eﬀects on brain oxygen and glucose consumption,
their actions diﬀer from one another [47–51].
Volatile Anesthesia. Isoﬂurane diminishes cerebral metab-
olism, preserving high-energy phosphates and inducing ex-
tracellular glucose elevation [47, 48, 51]. Conﬂicting data
have been reported about isoﬂurane’s eﬀect on lactate
production ranging from nonaccumulation to elevation of
300% [51]. However, a microdialysis study reported that
lactate elevation is associated with a concomitant pyruvate
elevation without changes in the lactate/pyruvate (L/P) ratio
and in glucose or glutamate concentrations [51]. Further-
more, isoﬂurane decreases insulin secretion predisposing the
patient to hyperG [50, 52].
IntravenousAnesthetics. Barbiturates(BBT)are depressors of
global metabolism without production of lactate accumula-
tion. They have no relevant eﬀects on systemic glucose regu-
lation [51].
Propofol causes a minimal elevation in extracellular
glucose[51].Unlikeisoﬂurane,itstimulatesinsulinsecretion
and, therefore, is less likely to generate hyperG [52].
Ketamine produces a mild-to-moderate rise in cerebral
oxygen and glucose consumption. It also increases cerebral
lactate levels moderately [51].
Opioidsdonothavemajoreﬀectsonglucosemetabolism.
Etomidate inhibits ACTH secretion and could, therefore,
induce hypoG [47–51].
Benzodiazepines decrease cerebral metabolic consump-
tion globally, maintaining dose-dependent coupling with the
CBF [47–51].
Neuroaxialanestheticsblocktheautonomicandneuroen-
docrine response to hypoG when used in spinal or epidural
anesthesia [50].
2.7. Target Blood Glucose Levels in Neurosurgery:
Clinical Studies
2.7.1. Intensive Insulin Therapy. In 2001, Van Den Berghe
published the results of a new therapeutic modality directed
to keep blood glucose between 80 and 110mg/dL (4.4
and 6.2mmol/L) called “intensive insulin therapy” (IIT)
[5]. This was a prospective, randomized, single-center trial
including 1564 patients of whom 60% were postcardiac
surgery. Patients randomized to IIT were compared with
a group that had blood glucose targets between 180 and
200mg/dL (10.0 and 11.1mmol/L). A signiﬁcant decrease in6 Anesthesiology Research and Practice
mortality (8% versus 4.6%, P<0.04) was observed mainly
in septic patients with multiorgan dysfunction and more
than ﬁve days in the critical care unit. Additional beneﬁts
were decreased incidence of infections and reduced rates
of mechanic ventilation, hospital mortality, polyneuropathy,
blood transfusions, and dialysis in patients with acute renal
failure [5].
In 2009 a similar trial was published in diﬀerent critical
patient populations with controversial results. The recently
reported ﬁndings from the multinational Normoglycemia
in Intensive Care Evaluation—Survival Using Glucose Algo-
rithm Regulation (NICE-SUGAR) trial are particularly rel-
evant [53]. In this prospective, randomized, multicenter
trial, intensive and conventional blood glucose control were
compared in 6,104 patients in the intensive care unit with
diﬀerent medical and surgical pathologies. IV insulin was
used to achieve a blood glucose level of 81 to 108mg/dL (4.5
to 6.0mmol/L) in the intensive group and 144 to 180mg/dL
(8.0 to 10.0mmol/L) in the conventional group. At 90 days
after admission in the ICU, mortality in the intensive group
was signiﬁcantly higher (27.5% versus 24.9%; P = 0.02),
and was as severe as hypoG incidence (6.8% versus 0.5%,
P<0.001) [53].
A consensus statement of the American Association
of Clinical Endocrinologists and the American Diabetes
Association [8] has recommended revising glucose targets.
In critically ill patients, start treatment at a threshold of
>180mg/dL (>10.0mmol/L), preferably with IV insulin
therapy, and maintain the glucose level between 140 and
180mg/dL (7.8 and 10.0mmol/L). Greater beneﬁt may be
obtained at the lower end of this range. Glucose concentra-
tions <110mg/dL (6.0mmol/L) are not recommended [8].
However, these goals should be ﬂexible and individualized
to the particular patient and the clinical circumstances [8].
Persistently elevated readings indicate that the treatment
regimen must be adjusted or changed and should alert the
treating physician of the need to explore the possible reasons
for hyperG [8].
2.7.2. Mixed Neurosurgical Populations. Two retrospective
studies, with methodological limitations from Brazil and
Australia, came to the same conclusion in neurosurgical
patients [54, 55]. IIT was associated with a greater risk of
developing hypoG without reducing mortality or improving
neurologic functional status [54, 55]. In a prospective, ran-
domizedcontrolledtrial,Bilottaetal.[32]analyzedthesafety
proﬁle and eﬃcacy of an aggressive blood glucose control
[80–110mg/dL (4.4–6.2mmol/L)] versus control manage-
ment [180–216mg/dL (10.0–12.0mmol/L)] in an unselected
neurosurgery population. Early enteral or parenteral feeding
was started with standard regimes. The therapeutic protocol
was followed until patients were discharged from the ICU
or until the second week after surgery. Although the length
of stay in the ICU and infection rate were lower in the
group of patients receiving intensive treatment, the number
of hypoG episodes were higher, without any diﬀerence in
mortality or functional results at six months after surgery
[32].
2.7.3. Aneurysmal Subarachnoid Hemorrhage and Intrac-
erebral Hemorrhage. Hematoma evacuation and aneurysm
clipping are common reasons for presentation to the oper-
ating room. Many patients who present for clipping have
already experienced some degree of aneurysmal subarach-
noid hemorrhage or intracerebral hemorrhage (SAH/ICH).
After SAH/ICH regional abnormalities in CBF, posthemor-
rhage edema, vasospasm, and increased ICP all predispose
the brain tissue to ischemia [56–61]. Despite the apparent
link between hyperG and symptomatic vasospasm, infarct
size, and outcome, the few studies of IIT in these populations
havefailedtodemonstrateasigniﬁcantdiﬀerenceinoutcome
with tight glucose control [61–63]. All but one of the
studies were retrospective, and target ranges were generally
under 140mg/dL (7.8mmol/L). The groups treated with
IIT developed signiﬁcantly fewer infections than the control
group (27% versus 42%; P<0.001), but the beneﬁt was a
reduction in the prevalence of postsurgery vasospasm. Nei-
ther mortality nor functional outcomes were aﬀected [34].
Recently Latorre et al. [64] compared glucose management
in two diﬀerent time periods in patients with aneurysmal
SAH in a retrospective analysis. Before 2003, blood glucose
was corrected if the levels were >200mg/dL (>11.1mmol/L);
after 2003, blood glucose was controlled more strictly and
aggressively maintaining levels between 80 and 140mg/dL
(4.4–7.8mmol/L). There were no diﬀerences in ﬁnal out-
comes between the groups, but there was a tendency for
improvement in patients treated to a plasma glucose range
of 80–140mg/dL (4.4–7.8mmol/L) [64]. In general, hyperG
is linked with worse outcome. While insulin therapy in SAH
patients was shown to eﬀectively control plasma glucose
levels, plasma glucose control is not necessarily reﬂective of
cerebral glucose such that very tight glucose control may
lead to neuroglycopenia. However, tight glycemic control is
associatedwithanincreasedriskforhypoGwhichwaslinked
to worse outcome [57].
These data suggest that a beneﬁt from tighter glucose
control during acute episodes of ischemia (such as with
temporary clip application or aneurismal rupture) would be
mechanistically plausible. It seems appropriate to consider
stricter control when acute, focal ischemia is occurring
or anticipated, but continuation of tight control into the
postoperative phase is not supported by the literature.
In ICH, admission hyperglycemia is associated with
increased 30-day mortality and worse functional outcome
[65–67]. Decline in serum glucose concentration correlated
with reduction in proportion of subjects with hematoma
expansion and decrease of poor clinical outcome [65].
However, the targets for glycemic control are unclear, and
there is increasing evidence that “tight” glycemic control
with insulin infusion can be associated with a critically low
cerebralextracellularglucoseconcentrationafterbraininjury
[68]. Until further data become available, systemic glucose
levels should not be treated in the acute phase after ICH
unless >180mg/dL (>10mmol/L) [10], although it seems
reasonable to treat patients with insulin when their periph-
eral glucose value is greater than 150mg/dL (>8.3mmol/L)
[16, 44].Anesthesiology Research and Practice 7
2.7.4. Severe Traumatic Brain Injury. A substantial body of
literature exists regarding glucose management in patients
with TBI [35, 69–71]. It is clear that TBI represents a
continuum of injury with heterogeneous changes in regional
brain function and glucose metabolism. Under certain
circumstances, cerebral hypoG may be a signiﬁcant concern
that complicates management. Thus, these studies do not
show a relevant clinical beneﬁt in using IIT in severely head-
injured patients [35, 69–71].
2.7.5. Spine Surgery. There are no speciﬁc studies of periop-
erative glucose management in patients undergoing spinal
surgery for tumor or correction of scoliosis. In 1989,
Drummond and Moore [72] reported that, in rabbits,
glucose administration prior to temporary spinal cord
ischemia dramatically increased the likelihood of paraplegia.
Woodworth et al. [73] reported, in a retrospective study,
that a single preoperative episode of hyperG in patients
undergoingintramedullaryspinaltumorresectioncorrelated
with a likelihood of poor postoperative ambulatory function
[73].Ifthemechanismofanticipatedspineinjuryisassumed
to be focal ischemia, it seems reasonable to extend the
models of acute focal ischemia to the spine and conclude
that pronounced hyperG immediately prior to hardware
manipulation has the potential to worsen the extent of
injury.Judicioususeofinsulintomaintainbloodglucoseless
than 150mg/dL (8.3mmol/L) before and during periods of
potential ischemia is prudent and safe.
2.7.6. Neurosurgery for Tumors and Intracranial Masses.
There are no speciﬁc studies of perioperative management
of glucose in patients with intracranial mass. Most patients
presenting for tumor resection receive perioperative corti-
costeroids. This therapy is associated with increased plasma
glucose and also with decreased cerebral glucose utilization
[30]. In a retrospective study, McGirt et al. [74] showed
an association between persistent postoperative hyperG and
mortality in patients undergoing tumor resection. The use
of glucose-containing solutions to replace water deﬁcit in
the perioperative period should be avoided in patients
undergoing resection of a pituitary mass due to the high
risk of developing central diabetes insipidus during the late
intraoperative, or, more commonly, postoperative period
[75, 76].
2.7.7. Interventional Neuroradiology (Tissue Plasminogen
Activator and Vasospasm). With increasing frequency,
patients present to the interventional radiology suite for
aneurysm coiling, injection of intra-arterial recombinant
tissue plasminogen activator (rTPA) after acute stroke,
and intra-arterial vasodilatory agents to treat symptomatic
vasospasm. These are clinical circumstances in which a
very acute ischemic episode has occurred, and the clinical
intervention may be accompanied by sudden reperfusion.
Non-DM patients with acute middle cerebral artery (MCA)
ischemia who received IV rTPA had larger cerebral stroke
volume, and worse 28-day outcome if hyperG (>180mg/dL)
was present [77]. However, glucose was measured on
admission and immediately treated with insulin if elevated.
One intriguing ﬁnding was that two patients in the
hyperglycemic group, who were treated with insulin prior
to emergency department arrival, had outcomes similar to
the normoglycemia group [77]. In a cohort of 1083 stroke
patients, Poppe et al. [78] reported that admission hyperG
[>144mg/dL (>8.0mmol/L)] was associated with greater
risk of ICH, mortality, and poor 90-day outcome after
intravenous tissue plasminogen activator (TPA). Similar
results are conﬁrmed in other studies [79, 80]. Most of
these data are retrospective and based on a single glucose
measurement in a largely diabetic population, so clear
conclusions cannot be drawn. However, it seems prudent
to obtain peripheral blood glucose measurements in every
patient who presents for intra-arterial thrombolysis or
treatment of symptomatic vasospasm and to treat values
greater than 144mg/dL (>8.0mmol/L) with insulin during
the immediate periprocedure period.
3.IIT:SystematicReview and
Published Guidelines
Recently a systematic review was published from a meta-
analysis of 21 trials in heterogenic populations of critically ill
patients,includingstrokeandheadtrauma[81].Onthebasis
of this systematic review, the American College of Physicians
recommendednotusingIITunderanycircumstancesinhos-
pitalized patients [82]. Actually, tight blood glucose control
does not have any solid evidence for its implementation in
the perioperative neurosurgical period or in victims of any
cerebral injury from any cause [12, 13, 33].
3.1. Intracerebral Hemorrhage. Current guidelines from the
American Heart Association recommend insulin treatment
for patients with blood glucose levels >185mg/dL
(>10.3mmol/L) and possibly even those with levels
>140mg/dL (>7.8mmol/L: evidence Class IIa, Level of Ev-
idence C) [83]. In contrast, ICH guidelines endorsed by the
major European stroke and neurological societies suggest
maintaining blood glucose below 300mg/dL (16.7mmol/L)
[39].
3.2. Subarachnoid Hemorrhage. Recently published guide-
lines from the American Heart Association emphasize the
importance of avoiding hyperG in patients with aneurysmal
SAH, but without providing speciﬁc recommendations on
target glucose levels [40].
3.3. Traumatic Brain Injury. Guidelines from the Brain
Trauma Foundation [41] and the European Brain Injury
Consortium [84] highlight the association of hyperG with
worse prognosis after severe brain trauma, but these doc-
uments do not specify which glucose level should be
considered as a trigger for initiating insulin therapy.
3.4. Acute Spinal Cord Injury. Recently, the consortium for
Spinal Cord Medicine published practical guidelines for
the acute management of spinal cord injury in adults8 Anesthesiology Research and Practice
online (http://www.pva.org). They recommend maintaining
serum glucose values between 80 and 110mg/dL (4.4 to
6.2mmol/L), albeit acknowledging a low level of evidence to
support such recommendation.
4. Glucose VariabilityandMonitoring
There are no guidelines or recommendations establishing
the method of choice and optimal monitoring frequency.
The American Diabetes Association [8] suggests “frequent”
monitoring, while the “Surviving Sepsis Campaign” suggests
monitoring every 1-2 hours [85].
Glucose levels ﬂuctuate continuously, and minimal vari-
ations are induced by multiple factors, such as stress, pain,
trauma, surgery, and drugs [86]. Wide variations constitute
an independent mortality predictor in critical patients,
perhaps reﬂecting the severity of the insult [87]. To date the
reasonforthisphenomenonhasnotyetbeenelucidated.One
hypothesis is that increased glucose variability is caused by
oxidative stress secondary to brain damage [88].
Few studies have elucidated the time course of blood
glucose after brain injury. In ischemic stroke, Baird et al.
[89] observed hyperG at admission in 35% of his patients;
43% of the patients continued to have elevated levels for
72 hours. Of the patients with normal levels at admission,
46% develop hyperG later. In a similar population, Allport
et al. [90] identiﬁed an early (within 8 hours after stroke
onset) and later (48–88 hours) hyperG, and Godoy et al.
[44] identiﬁed four diﬀerent evolutional patterns in patients
with spontaneous ICH, showing a diﬀerent impact on early
mortality.
4.1. Monitoring. There are diﬀerent forms of monitoring,
but all use enzymatic reactions (glucose oxidase or dehydro-
genase). It is easy to obtain arterial or venous blood samples;
capillary or subcutaneous samples must be obtained using
sensors inserted in the abdominal wall [89, 90]. Plasma glu-
cose samples are the gold standard (about 11% higher than
obtained by whole blood) by conventional laboratory meth-
ods [8], but obtaining them requires extreme precautions to
avoid contamination with parenteral solutions. Some blood
gas analyzers that allow obtaining fast and reliable glucose
values are not always available in the ICU or operating room.
The accuracy of a blood glucose monitor can be aﬀected
by several factors: type of blood glucose strip and monitor,
very low glucose values, presence of edema, anemia, and
peripheral hypoperfusion [8, 15, 17]. Devices used for blood
sugar measurements are calibrated to obtain plasma glucose
with normal hematocrit values [17]. If hematocrit decreases,
the blood glucose level can be overestimated by up to 30%
[15]. Interfering substances, such as drugs commonly used
in critically ill patients, may account for additional causes of
error in determining blood glucose concentrations (Table 6).
S u b c u t a n e o u ss e n s o r sd e t e r m i n eb l o o dg l u c o s el e v e l so na
continuous basis (every few minutes) by measuring glucose
levels of interstitial ﬂuid. These continuous systems must
be calibrated with a traditional blood glucose measurement
(using current technology). Glucose levels in interstitial ﬂuid
Table 6: Capillary glucose monitoring with test strips: factors
interfering with correct determination.
(i) Factors overestimating the accurate value (false rise)
Anemia
Paracetamol
Dopamine
Mannitol
Hyperuricemia
Vitamin C
Jaundice
Immunoglobulins
(ii) Factors underestimating the accurate value (false drop)
High hematocrit (polycythemia—COPD)
Hypoperfusion
Noradrenaline (high doses)
Edema
Hypoglycemia
paO2 > 100mmHg
lag behind blood glucose values [15, 17]. Furthermore, they
have not been validated for routine utilization in critically
ill patients or intraoperatively [89, 90]. Vascular sensors that
allow continuous monitoring are in development.
4.2. Nutrition for Blood Glucose Control. A strategy of blood
glucose control should include a nutrition protocol with
the preferential use of the enteral route [8, 14, 15, 35,
38, 91]. Initiating blood glucose control without adequate
provision of calories and carbohydrates will increase the
risk of hypoG [8, 14, 15, 35, 38, 91]. This strategy of
strict blood glucose control should be carefully coordinated
with the level of nutritional support and metabolic status,
which changes frequently in neurocritically ill patients. A
recent study, evaluated the nutrition protocol’s inﬂuence on
brain metabolism using microdialysis in patients with SAH
[38]. Two hours after 250Kcal by nasojejunal tube feeding,
there were simultaneous increments in glucose levels in the
blood and cerebral extracellular space without a change of
glutamate concentration or the L/P ratio [38]. Stress hyperG
exacerbates the disorders in gastric motility as a result of
several factors such as cytokines produced by inﬂammation,
oxidative stress, vasoactive intestinal peptides, splanchnic
hypoperfusion, and drugs such as phenytoin, steroids, and
opioids[91].Acutegastroparesisdiﬀersfromdiabeticgastro-
paresisinthatitisreversibleandsensitivetoprokinetics[91].
Acute gastroparesis causes an interruption of appropriate
feeding,whichcontributesinawidervariabilityinbloodglu-
cose levels, showing an increase in insult severity. However,
solid clinical evidences and practical considerations are not
provided for nutrition support regimens to minimize stress
hyperGandassistglucosemanagement.Actualguidelinesare
basedonsmallpatientseriesandexpertopiniononly[91].In
Table 7 weshowcurrentrecommendations(expertsopinion)
for good glucose control during nutritional support [91].Anesthesiology Research and Practice 9
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Figure 2: Suggested glycemic targets during acute brain injury/neurosurgery. Where L/P: Lactate/Pyruvate and BBB: Blood–brain barrier.
Table 7: Recommendations for adequate nutritional support
during glucose control protocol.
(i) Avoid excessive caloric intake especially carbohydrates
(ii) No more than 25–30 calories per kg body weight per day
(iii) 25% of intake in the form of lipids
(iv) Insulin therapy according to needs
5. Management of Hypoglycemia
No speciﬁc trial has addressed the question of what the
best management of hypoG is, while experimental data
suggest new strategies to reduce brain damage due to
severe hypoG [92]. Nowadays, IIT is the most prevalent
cause of the development of hypoG. Available evidence
suggests that hypoG must be avoided by all means and must
be treated urgently, because it is closely linked to worse
short- and long-term outcomes [6–8, 42]. We recommend
implementing alerts when blood glucose values are near
90mg/dL (5.0mmol/L) in neurocritically ill patients because
microdialysis monitoring showed that even normal blood
glucose levels can also induce cellular derangement in brain-
injured patients [59, 68].
6. Conclusions andFutureDirections:
WhatIstheOptimalGlucose Level?
T h eo p t i m a lr a n g eo fb l o o dg l u c o s el e v e l si nn e u r o s u r g i c a l
and neurocritically ill patients has not been determined
and remains controversial. No consensus exists on blood
glucose level goals for the perioperative period; however,
several organizations have established general targets for
neurocritically ill and neurosurgery patients [12, 16]. The
question of optimal blood glucose goals cannot be answered
with certainty, especially in neurocritically ill patients [12,
13, 16, 30, 33]. The brain is very vulnerable to extreme
blood glucose level variations. It was demonstrated that an
energycrisismayevenoccurwithbloodglucoselevelswithin
normal range [59, 68]. Therefore, it would be essential to
know what the safe lower limit is. However, neither PET
scanners nor microdialysis are available in every ICU. The
American Diabetes Association and the American Associa-
tion of Clinical Endocrinologists [8], based on the available
evidence, set an upper limit at 180mg/dL (10mmol/L), at
which insulin therapy should be started. This would also
propose to maintain blood glucose levels between 140 and
180mg/dL(7.8–10.0mmol/L)[8]incriticallyillpatientsand
in the perioperative period. The available clinical data do
not support tight glucose control with IIT in this critically
ill subpopulation [12, 16]. Two meta-analyses of all patient
types treated with IIT drew similar conclusions [81, 82].
Figure 2 outlines where blood sugar levels should be kept
in patients with acute brain injury, while Figure 3 shows our
proposal for an algorithm in hyperglycemia management to
use in neurocritically ill patients.
Ongoing and future research promises to clarify the
present muddled picture. Examples include stratiﬁcation of
neurologic-injury-based protein and biochemical biomark-
ers and identifying potential high-throughput strategies that
will allow one to individualize disease management.
Further studies on the multimodal eﬀects of insulin via
modulation of signaling pathways, such as inﬂammation,
cell adhesion, and activity of glucose transporters and
pyruvate metabolism enzymes, will have to be conducted.
Investigation of agents other than insulin, such as glucagon-
like peptide-1 (GLP-1), for glucose-lowering eﬀects may
demonstrate a reduced rate of hypoG or other beneﬁcial
metabolic eﬀects. Microdialysis studies in patients under-
going IIT therapy could provide important insight into
regional alterations of glucose metabolism in injured brain
tissue. Neurocritically ill patient populations are heteroge-
neous, and data interpretation and generalization has to
be done with caution. We need a better understanding of
all these pathophysiological processes before adoption of
IIT.
Finally, special attention should be drawn to the opti-
mal technology for accurate, reliable, and rapid glucose
measurement. Closed-loop continuous glucose control sys-
tems should be developed. New technologies may facili-
tate the avoidance of hypoG under an IIT regimen and
the development of IIT protocols that can be individual-
ized to the speciﬁc metabolic state of the patient under
treatment.10 Anesthesiology Research and Practice
Serial monitoring
Diabetic patients Nondiabetic patients
Stop
Early nutrition
Hyperglycemia
IV insulin
Yes No
Reactive regimen Proactive regimen
Oral antidiabetic agents 
Long-acting insulin
Normal glycemia
monitoring
Follow-up
Hyperglycemia  
(>150mg/dL)
mechanical ventilation, sepsis, hyperosmolar state,  
ketoacidosis, postoperative period
Target (mg/dL)
>100<150
Glycemia > 350mg/dL,
Figure 3: Algorithm proposed for hyperglycemic management.
6.1. Key Points
(i) hyperG is frequent in acute neurological diseases
in the perioperative period both in diabetics and
nondiabetics. hyperG [>150mg/dL (>8.3mmol/L)]
isassociatedwithpooroutcome,butcausalityhasnot
been deﬁnitively demonstrated.
(ii) Extreme hypoG and hyperG episodes must be avoid-
ed.
(iii) It is recommended to maintain blood glucose levels
between 140 and 180mg/dL (7.8–10.0mmol/L).
(iv) Oral antidiabetic agents have no place in acute and
critical situations.
(v) Regular intravenous insulin is preferred to lower
blood glucose levels.
(vi) IIT has no beneﬁts.
(vii) Frequently and routinely monitor glucose levels.
(viii) Implementation of an institutional multidisciplinary
management protocol is recommended.
(ix) Therapy must be accompanied by adequate nutri-
tional support.
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